SNY — Sanofi catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

15 verified catalyst event(s) for Sanofi (ticker SNY). Each is linked to its official source. Verified as of 2026-11-04.

Next verified catalyst

2026-11-26 — Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at · official source ↗

Upcoming

Date	Event	Company	Drug	Official source & verification
2026-11-26 in 22d ESTIMATED	READOUT Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and Phase 4 · COVID-19	SNY Sanofi	Omicron Subvariant-Based SARS-CoV-2 Reco	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-28 in 24d ESTIMATED	READOUT A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric P Phase 3 · Yellow Fever Immunization	SNY Sanofi	Yellow fever vaccine (live), Yellow feve	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Pha Phase 3 · Immune Thrombocytopenia	SNY Sanofi	rilzabrutinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-12-01 in 27d ESTIMATED	READOUT Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Phase 3 · Pneumococcal Infections	SNY Sanofi	PCV21, 20vPCV	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-12-01 in 27d ESTIMATED	READOUT Study to Evaluate the Safety and the Immunogenicity of a Second Generation Struc Phase 1/2 · Pandemic Influenza Immunization, Healthy Volunteers	SNY Sanofi	Pandemic flu H5 HA mRNA SD2 vaccine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-12-17 in 1mo ESTIMATED	READOUT A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Cr Phase 2 · Crohn's Disease	SNY Sanofi	brivekimig	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-12-17 in 1mo ESTIMATED	READOUT A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participan Phase 2 · Ulcerative Colitis	SNY Sanofi	SAR442970	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-12-23 in 2mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzab Phase 2 · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion	SNY Sanofi	frexalimab, brivekimig, rilzabrutinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-07 in 2mo ESTIMATED	READOUT Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children Phase 3 · Sickle Cell Disease	SNY Sanofi	PCV21, 20vPCV	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-18 in 3mo ESTIMATED	READOUT Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candid Phase 1/2 · Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization	SNY Sanofi	Investigational hMPV/RSV vaccine, Invest	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-19 in 3mo ESTIMATED	READOUT A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Phase 1/2 · Solid Tumor	SNY Sanofi	SAR445877, Cetuximab, ADG126, Bevacizuma	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-02-09 in 3mo ESTIMATED	READOUT Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa Phase 2 · Hidradenitis Suppurativa	SNY Sanofi	Brivekimig	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-02-11 in 3mo ESTIMATED	READOUT A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Partici Phase 2 · Graves' Disease	SNY Sanofi	Rilzabrutinib dose 1, Rilzabrutinib dose	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-02-17 in 4mo ESTIMATED	READOUT An Extension Study to Investigate the Long-term Safety and Tolerability of Itepe Phase 3 · Chronic Rhinosinusitis With Nasal Polyps	SNY Sanofi	Itepekimab (SAR440340)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-03-16 in 4mo ESTIMATED	READOUT Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Phase 4 · Asthma	SNY Sanofi	Dupilumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change